-
Mashup Score: 21Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update - 2 day(s) ago
Tisagenlecleucel responses in patients with r/r FL remain highly durable a year after primary analysis; no new safety signals were observed.Low levels of L
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Espacio Europeo de Datos Sanitarios (EEDS) - 2 day(s) ago
El Espacio Europeo de Datos Sanitarios es un ecosistema específico para la salud formado por reglas, normas y prácticas comunes, infraestructuras y un marco de gobernanza cuyo objetivo es…
Source: health.ec.europa.euCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study - 4 day(s) ago
In the single-arm, open-label, multicenter, phase 2 PILOT study, second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) for whom hematopoietic stem cell transplantation (HSCT) was not intended resulted in high response rates, durable responses, and a safety profile consistent with previous reports. Here, we analyzed changes in health-related quality of life (HRQOL) in patients who received liso-cel in PILOT. Patients received liso-cel, an autologous, CD19-directed, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells, for a total target dose of 100 × 10⁶ CAR+ T cells. HRQOL, a secondary endpoint of PILOT, was assessed as prespecified using 3 patient-reported outcome instruments (EORTC QLQ-C30; FACT-LymS; EQ-5D-5L). Evaluable datasets for the EORTC QLQ-C30, FACT-LymS, EQ-5D-5L health utility index, and EQ-5D visual ana
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9VIDEO: Impacto del estado funcional en el tratamiento hematológico del paciente mayor | ScienceLink - 4 day(s) ago
Escuchar en Spotify: https://open.spotify.com/episode/2UINaPIMC7eDu3396f2w0W El Dr. Raúl Córdoba, hematólogo, Jefe Asociado de Hematología y Coordinador de la Unidad de Linfomas en el Hospital Universitario Fundación Jiménez Díaz en Madrid, España, presenta en breves minutos sobre adaptar tratamientos según la fragilidad del paciente mayor con cáncer hematológico, al margen del pasado Congreso Iberoamericano de Neoplasias Linfoproliferativas…
Source: sciencelink.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Analysis of @DrRaulCordoba FOLLOWERS - 6 day(s) ago
Mis seguidores viven en España(45%),Estados Unidos(22%),UK.(6%) y más tweepsmap.com/!DrRaulCordoba
Source: fedica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45
Frailty, defined as an age-related state of increased vulnerability to acute stressors, is a major challenge in the care of older people with haematological malignancies. Growing evidence from multiple studies suggests that a systematic evaluation of frailty in these patients by use of appropriate assessment tools might help clinicians to make appropriate treatment decisions and initiate frailty interventions. Here, we summarise current knowledge on the origin, decision relevance, assessment methods, and possible treatments of frailty in older people with haematological malignancies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Problemas de suministro de cisplatino 1 mg/ml concentrado - 10 day(s) ago
La AEMPS informa de problemas de suministro de cisplatino 1 mg/ml concentrado para perfusión y recomendaciones para priorización.
Source: www.aemps.gob.esCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Problemas de suministro de cisplatino 1 mg/ml concentrado - 11 day(s) ago
La AEMPS informa de problemas de suministro de cisplatino 1 mg/ml concentrado para perfusión y recomendaciones para priorización.
Source: www.aemps.gob.esCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Problemas de suministro de cisplatino 1 mg/ml concentrado - 12 day(s) ago
La AEMPS informa de problemas de suministro de cisplatino 1 mg/ml concentrado para perfusión y recomendaciones para priorización.
Source: www.aemps.gob.esCategories: General Medicine News, Hem/OncsTweet
#Hematology Durable response after tisagenlecleucel in adults with relapsed/refractory #follicular #lymphoma: ELARA trial update | @BloodJournal | American Society of Hematology @ASH_hematology #lymsm #CARTcell https://t.co/344nzOE4Rd